Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a prespecified pooled analysis showed semaglutide improves symptoms and reduces frailty burden across frailty strata in obesity-related HFpEF; long-term VALOR-HCM data demonstrated sustained reverse remodeling with mavacamten up to 128 weeks in obstructive HCM; and a large cohort study found PREVENT risk equations may underestimate ASCVD risk in statin-naive patients, whereas PCE estimates were closer for untreated risk.
Summary
Three impactful cardiology studies stood out today: a prespecified pooled analysis showed semaglutide improves symptoms and reduces frailty burden across frailty strata in obesity-related HFpEF; long-term VALOR-HCM data demonstrated sustained reverse remodeling with mavacamten up to 128 weeks in obstructive HCM; and a large cohort study found PREVENT risk equations may underestimate ASCVD risk in statin-naive patients, whereas PCE estimates were closer for untreated risk.
Research Themes
- Heart failure therapeutics and frailty targeting
- Disease modification in obstructive hypertrophic cardiomyopathy
- Calibration of ASCVD risk prediction under treatment exposure
Selected Articles
1. Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
In a prespecified pooled participant-level analysis of STEP-HFpEF, semaglutide produced similar weight loss across baseline frailty strata but greater improvements in HF symptoms and physical limitations among more frail participants, and it reduced overall frailty burden over 52 weeks. Safety was consistent across strata.
Impact: Demonstrates that semaglutide benefits extend to highly frail HFpEF patients and can reduce frailty burden, informing treatment across a vulnerable subgroup.
Clinical Implications: Supports semaglutide use in obesity-related HFpEF irrespective of frailty, with expectations for symptom improvements and potential frailty reduction; clinicians can counsel frail patients about comparable weight loss and enhanced symptomatic benefit.
Key Findings
- Weight loss with semaglutide was similar across nonfrail, more frail, and most frail strata over 52 weeks.
- Greater improvements in KCCQ-Clinical Summary Score were observed in more frail participants.
- Semaglutide reduced cumulative frailty index–derived frailty burden after 52 weeks.
- Safety profile did not materially differ by frailty status.
Methodological Strengths
- Prespecified pooled participant-level analysis of randomized trials
- Dual primary endpoints with standardized, validated measures (KCCQ-CSS, body weight)
Limitations
- Subgroup analysis; not powered for hard clinical outcomes or mortality
- Frailty measured via cumulative deficit index; generalizability outside trial populations may be limited
Future Directions: Evaluate long-term effects on hospitalization and mortality, mechanistic links between weight loss and frailty reduction, and implementation strategies in real-world frail HFpEF populations.
BACKGROUND: Frailty is common in heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program, semaglutide improved heart failure (HF) symptoms and physical limitations and reduced body weight (BW) in participants with obesity-related HFpEF. Whether the efficacy and safety of semaglutide vary by frailty and the effects of semaglutide on frailty are unknown. OBJECTIVES: This study sought to evaluate the efficacy of semaglutide in participants with obesity-related HFpEF according to frailty status at baseline. METHODS: The authors performed a prespecified, pooled, participant-level analysis of the STEP-HFpEF program that included participants with obesity-related HFpEF. Participants were randomized to once-weekly semaglutide, 2.4 mg, or placebo for 52 weeks. Dual primary endpoints were changes in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and BW. Frailty was estimated using a cumulative deficit-derived frailty index comprising 34 variables across multiple domains at baseline and follow-up. Efficacy and safety of semaglutide were evaluated in participants across 3 baseline frailty strata. Effects of semaglutide on frailty burden were also assessed. RESULTS: Of the 1,145 participants, 110 (9.6%) were nonfrail, 343 (30.0%) were more frail, and 692 (60.4%) were most frail. Semaglutide-mediated weight loss was similar across frailty strata (P
2. Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks: Insights From the VALOR-HCM Trial.
Over 128 weeks in VALOR-HCM, mavacamten produced durable improvements in LVOT gradients, LV mass, diastolic indices, and LA/LV strain, aligning with quality-of-life gains, supporting disease modification in obstructive HCM referred for septal reduction therapy.
Impact: Provides long-term mechanistic and clinical evidence that cardiac myosin inhibition sustains reverse remodeling in obstructive HCM, informing treatment decisions and potential deferral of septal reduction therapy.
Clinical Implications: For symptomatic obstructive HCM patients referred for septal reduction, mavacamten can achieve sustained gradient reduction and structural/functional improvement, potentially delaying or obviating invasive therapy while improving quality of life.
Key Findings
- Sustained LVOT gradient reductions at 128 weeks: resting −61%, post-Valsalva −72%, postexercise −53% (all P < 0.05).
- Structural and functional remodeling: LV mass index −11%, septal E/e' −18%, LV GLS +4.5%, LA volume index −6%, LA strain (conduit +16%, contraction +35%, reservoir +32%).
- Patients with ≥5-point KCCQ-23-CSS improvement exhibited significant and sustained LA/LV strain improvements; minimal KCCQ change paralleled lack of strain gains.
Methodological Strengths
- Randomized design with long-term open-label extension to 128 weeks
- Comprehensive echocardiography including vendor-neutral LV/LA strain analysis
Limitations
- Open-label extension phase; potential bias and survivor effects
- Population highly selected (referred for septal reduction); no hard outcome adjudication
Future Directions: Assess effects on clinical endpoints and healthcare utilization, define predictors of response, and explore sequencing with or instead of septal reduction therapy.
BACKGROUND: In the VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy; NCT04349072) trial, patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten demonstrated significant improvement in left ventricular outflow tract (LVOT) gradients and echocardiographic indices of cardiac remodeling in the short term. OBJECTIVES: The authors sought to assess whether mavacamten results in sustained favorable long-term cardiac remodeling at 128 weeks (end of trial). METHODS: A total of 112 adult symptomatic obstructive HCM patients (mean age: 60.3 years; 50% men; and 94% NYHA functional class III/IV) who were referred for septal reduction therapy were randomized 1:1 to mavacamten or placebo for 16 weeks. Subsequently, placebo patients transitioned to and received 112 weeks of mavacamten, and the original mavacamten group received 128 weeks of mavacamten. All patients had comprehensive echocardiographic assessments (including LV and left atrial [LA] global longitudinal strain measurements using vendor neutral software [TOMTEC-ARENA TTA2, Philips Healthcare]) at baseline and 128-week follow-up. RESULTS: At week 128, there was a sustained improvement (mean percentage of change from baseline, all P < 0.05) in LVOT gradients (resting [-61%], post-Valsalva [-72%], and postexercise [-53%]), LV mass index (-11%), septal E/e' (-18%), LV global longitudinal strain (4.5%), LA volume index (-6%), and LA strain (conduit strain [16%], contraction [35%], and reservoir [32%]). In 71 patients with ≥5 point improvement in the Kansas City Cardiomyopathy Questionnaire 23-item Clinical Summary Score (KCCQ-23-CSS), there was a significant and sustained improvement (all P < 0.05), whereas in 25 patients with <5 point improvement in the KCCQ-23-CSS, there was no significant improvement in various LA and LV strain values. CONCLUSIONS: In the VALOR-HCM trial, treatment with mavacamten resulted in sustained favorable cardiac remodeling, including improvement in LVOT gradients, cardiac volumes, cardiac hypertrophy, diastolic function, and markers of LA and LV strain from baseline through week 128, suggesting disease modification. These favorable changes also occurred in association with meaningful improvement in quality of life.
3. PREVENT and PCE Models for Estimating ASCVD Risk Stratified by Statin Exposure.
In 193,885 adults with 10-year follow-up, PCE and PREVENT had similar discrimination. PREVENT aligned better with observed risk overall, but in statin-naive patients PREVENT underestimated risk while PCE better approximated untreated risk, highlighting treatment exposure as a key calibration factor.
Impact: Challenges one-size-fits-all use of PREVENT by demonstrating underestimation in statin-naive patients, informing guideline discussions on model selection and shared decision-making for statin initiation.
Clinical Implications: When estimating untreated 10-year ASCVD risk to guide statin therapy, clinicians should consider using PCE in statin-naive patients and be cautious with PREVENT calibration under no-treatment conditions; treatment exposure during follow-up materially affects model performance.
Key Findings
- Discrimination similar: C-statistic 0.725 (PCE) vs 0.723 (PREVENT).
- Overall, PREVENT estimates more closely matched observed risk, whereas PCE tended to overestimate.
- In statin-naive patients, PREVENT underestimated risk (e.g., observed 8.2% vs estimated 5–<7.5%; observed 13.5% vs estimated 7.5–<10%), while PCE was closer to observed untreated risk.
Methodological Strengths
- Very large integrated health system cohort with decade-long follow-up
- Stratification by statin exposure during follow-up and comprehensive calibration assessment
Limitations
- Retrospective design with potential residual confounding and misclassification
- Generalizability may be limited to similar health systems and demographics
Future Directions: Prospective validation with explicit modeling of treatment exposure, dynamic risk updating, and external validation across diverse populations and health systems.
IMPORTANCE: The Predicting Risk of Cardiovascular Disease Events (PREVENT) equations are an updated model developed to improve on the Pooled Cohort Equation (PCE) for estimating 10-year atherosclerotic cardiovascular disease (ASCVD) risk. These equations facilitate patient-clinician discussions on initiating statin therapy and are used to estimate risk without treatment. However, statin exposure during follow-up was not fully accounted for in the development of these equations. OBJECTIVE: To assess the performance of the PCE and PREVENT equations in estimating ASCVD, accounting for statin exposure during follow-up. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included adults from an integrated health care system with 10-year follow-up data. Adults without diabetes or ASCVD were identified in 2013 and followed-up through December 31, 2023, with analyses performed in January 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was incident ASCVD. Estimated risks from PCE and PREVENT equations were compared with observed risks, with discrimination assessed via C statistics. The performance of these equations was evaluated in patient populations stratified by statin exposure during follow-up. RESULTS: Among 193 885 adults (median [IQR] age, 55 [48-63] years; 113 400 [58.5%] women), 6528 experienced an ASCVD event. The C statistic was 0.725 (95% CI, 0.719-0.731) for PCE and 0.723 (95% CI, 0.716-0.729) for PREVENT. In the overall population, regardless of statin exposure, the observed 10-year ASCVD risk was lower than estimated by PCE: 3.6% for individuals with estimated risk of 5% to less than 7.5%, 4.5% for those with estimated risk of 7.5% to less than 10%, and 8.0% for those with estimated risk of 10% or greater. The observed risk more closely aligned with the estimated risk from PREVENT: 5.2% for individuals with estimated risk of 5% to 7.5%, 8.1% for those with estimated risk 7.5% to less than 10%, and 11.6% for those with estimated risk of 10% or greater. In contrast, among patients not exposed to statin therapy during follow-up, PREVENT underestimated risk: observed risk was 8.2% for individuals with estimated risk of 5% to less than 7.5%, and 13.5% for those with estimated risk of 7.5% to less than 10%, while PCE-estimated risk more closely approximated the observed risk. CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, the PREVENT model underestimated risk in patients not treated with statins, whereas the PCE estimates more closely reflected what a patient's risk would be without statin therapy.